On the stock market since 2020, it operates in the everyday-essentials business. It has 613 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $300.8M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 9 buys and 8 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $1.50 — 90% above today’s price.
A loss of $9.5M against $300.8M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.79. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, SKIN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SKIN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.